Cargando…

Targeting HER2-positive breast cancer: advances and future directions

The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago. Sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, Sandra M., Shastry, Mythili, Hamilton, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640784/
https://www.ncbi.nlm.nih.gov/pubmed/36344672
http://dx.doi.org/10.1038/s41573-022-00579-0